Share ownership Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 19:24:30 2026-01-21 EST			5-day change	1st Jan Change
5,050.00 ^JPY	+1.53%		-1.88%	+4.51%

01-15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
01-13	Oncolytics Biotech Inc. Appoints Yujun Wu as Vice President, Head of Biostatistics	CI

Share class: Takeda Pharmaceutical Company Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	1,590,937,609	1,584,668,331 ( 99.61 %)	5,758,360 ( 0.3619 %)	99.61 %

Major shareholders: Takeda Pharmaceutical Company Limited

Name	Equities	%	Valuation
BlackRock Fund Advisors 3.734 %	59,401,184	3.734 %	1 837 M ¥
BlackRock Japan Co. Ltd. 2.264 %	36,014,900	2.264 %	1 114 M ¥
Amova Asset Management Co., Ltd. 2.152 %	34,232,400	2.152 %	1 059 M ¥
Nippon Life Insurance Co. 1.556 %	24,752,000	1.556 %	766 M ¥
BlackRock Advisors (UK) Ltd. 0.7856 %	12,498,388	0.7856 %	387 M ¥
BlackRock Investment Management (UK) Ltd. 0.4566 %	7,263,768	0.4566 %	225 M ¥
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.3953 %	6,288,500	0.3953 %	194 M ¥
BlackRock (Netherlands) BV 0.3613 %	5,748,780	0.3613 %	178 M ¥
Lazard Japan Asset Management KK 0.2191 %	3,486,500	0.2191 %	108 M ¥
Takeda Pharmaceutical Employee Incentive Plan 0.186 %	2,959,895	0.186 %	92 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Capital Research & Management Co. (Global Investors) 0.4213 %	13,404,129	0.4213 %	209 M ¥
Eaton Vance Management 0.2417 %	7,690,415	0.2417 %	120 M ¥
UBS Financial Services, Inc. 0.1833 %	5,833,119	0.1833 %	91 M ¥
Goldman Sachs Wealth Services LP 0.1557 %	4,953,331	0.1557 %	77 M ¥
Fidelity Management & Research Co. LLC 0.1316 %	4,186,946	0.1316 %	65 M ¥
Brandes Investment Partners LP 0.1236 %	3,931,803	0.1236 %	61 M ¥
Renaissance Technologies LLC 0.1215 %	3,864,600	0.1215 %	60 M ¥
Aperio Group LLC 0.1039 %	3,307,589	0.1039 %	52 M ¥
TD Securities (USA) LLC 0.0944 %	3,004,300	0.0944 %	47 M ¥
Arrowstreet Capital LP 0.0889 %	2,828,778	0.0889 %	44 M ¥
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	19.45%
Other	0.68%
Takeda Pharmaceutical Co., Ltd.	0.4%
Iyogin Holdings, Inc.	0.18%
Individuals	0.06%
ABC arbitrage SA	0.04%
Medipal Holdings Corp.	0.03%
The Shiga Bank, Ltd.	0.01%
SEI Investments Co.	0.01%
Unknown	79.14%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	9.37%
Japan	7.48%
United Kingdom	1.98%
Netherlands	0.52%
Canada	0.23%
France	0.19%
Sweden	0.15%
Ireland	0.14%
Taiwan	0.13%
Australia	0.12%
Norway	0.1%
Denmark	0.08%
Singapore	0.07%
Individuals	0.06%
Luxembourg	0.06%
Hong Kong	0.05%
Finland	0.04%
Germany	0.03%
Switzerland	0.03%
Mexico	0.01%
Spain	0.01%
Slovenia	0.01%
Austria	0.01%
Italy	0.01%
South Africa	0.01%

Based on 1000 largest holdings

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Employees

47,455

Sector

Pharmaceuticals

Calendar

01-29 - Q3 2025 Earnings Release

More about the company